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months ago) and were receiving GnRH with or without anti-
androgen, and had recent experience of hot ﬂushes as a result of
their therapy. A content and thematic analysis was conducted to
identify themes and categories that centred on particular phrases,
incidents and types of behaviour. RESULTS: Participants (n = 12)
aged 58–82, diagnosed on average for 5 years, receiving GnRH
agonists (100.0% Lupron, 40.0% Casodex, 20.0% Zometa)
were interviewed. The ﬁrst hot ﬂush usually occurred within 2
weeks of GnRH treatment. Participants experienced widely dif-
fering hot ﬂush event frequency and severity; from 8–10 events in
24 hours to one in 2–3 weeks. Events lasted 2 minutes to one
hour, and occurred at different times. Analyses identiﬁed that hot
ﬂushes were most commonly described in terms of ‘sweating’,
‘burning up’, and ‘perspiring’. Those who had more severe
ﬂushes also described ‘dizziness’, ‘weakness’, and ‘nausea’. Par-
ticipants found their hot ﬂush experience generally distressing
e.g. felt scared, anxious, annoyed, confused, irritated, worried.
Hot ﬂushes impacted men’s lives e.g. sleep problems, needing to
stop activities, resting, taking a cold shower. However, most
considered the hot ﬂush experience in the context of their overall
condition, some reported getting used to the experience over time
and adopting varies coping strategies. CONCLUSION: Hot ﬂush
descriptions reﬂect those previously reported in the literature,
provide additional depth to the experience from the patient’s
perspective and will inform the development of health states for
utility assessment.
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OBJECTIVE: Hodgkin’s lymphoma (HL) signiﬁcantly impacts
the health related Quality of Life (HRQoL) of patients. Treated
patients often report increased stress, fatigue, nausea, sexual
dysfunction, decreased social and emotional function, and
vocational limitations; however few studies have assessed these
domains. This review summarizes the impact of HL on hrQoL
and recommends which HRQoL constructs should be assessed in
the clinic and in clinical trials. METHODS: A systematic review
of the literature was conducted in order to better understand the
impact of HL and its treatments on HRQoL. The identiﬁed
articles were reviewed for references to HRQoL and speciﬁc tools
to assess these constructs. The major impacts of the disease and
treatment effects are compared across tools assessing these
domains. RESULTS: Some 30 published studies assessing hrQoL
in patients with HL were identiﬁed. In these 30 articles over 20
instruments were used to assess HRQoL. The most common
cancer-speciﬁc instruments employed were the EORTC QLQ-30
and various fatigue scales. No HL speciﬁc instrument was iden-
tiﬁed as being widely used. Tables summarizing the domains
covered by each instrument are provided. The EORTC and
FACT-Lym appear to provide the best coverage of relevant
HRQoL domains, however, using more than one instrument is
necessary to capture all relevant domains. CONCLUSION:
Although HL signiﬁcantly impacts HRQoL very few studies have
collected this data in a comprehensive manner. This work reviews
the literature on the HRQoL in patients with HL and provides
insights regarding the key set of HRQoL constructs that should
be assessed in the clinic and in clinical trials to best characterize
the impact of HL and treatment. Although the FACT-Lym pro-
vides good coverage of HRQoL domains in HL, additional vali-
dation work is needed to ensure the reliability and validity of the
tool in this population.
PCN71
SOCIETAL PREFERENCES (UTILITIES) FOR ADVANCED
MELANOMA HEALTH STATES INTHE UNITED KINGDOM (UK)
AND AUSTRALIA
Szabo SM1, Beusterien KM2, Kotapati S3, Mukherjee J3, Hoos A3,
Levy AR1
1Oxford Outcomes Ltd,Vancouver, BC, Canada, 2Oxford Outcomes
Ltd, Bethesda, MD, USA, 3Bristol-Myers Squibb Co,Wallingford, CT,
USA
OBJECTIVE: To estimate general public preference-based utili-
ties for standardized health states that include common responses
and toxicities observed during treatment of advanced melanoma.
METHODS: A cross-sectional study was used to elicit standard
gamble utilities for melanoma in the UK and Australia. Health
states included partial response (PR), stable disease (SD) and
progressive disease (PD). Common grade I/II toxicities (occurring
in >10% of patients) were abstracted from the literature for
dacarbazine, temozolomide, interleukin-2, fotemustine, and
interferon alpha2b. These may also apply for ipilumumab, a
developmental immunotherapy. Health state descriptions were
based on WHO response deﬁnitions, Common Toxicity Criteria
for Adverse events v3, and feedback from ﬁve clinical experts and
three quality-of-life researchers. RESULTS: Utilities were elicited
from 110 participants in the UK (n = 64) and Australia (n = 56).
Mean utilities estimated (for UK vs. Australian respondents)
were as follows: PR (0.85 vs. 0.89); SD (0.77 vs. 0.80); PD (0.59
vs. 0.44); and best supportive care (0.59 vs. 0.44). Utility decre-
ments associated with the toxicities were: hair loss (-0.03); skin
reaction (-0.03 vs. -0.08); diarrhea (-0.06 vs. 0.12); toxicity,
but indication that treatment may be working (-0.06 vs. -0.08);
nausea/vomiting (-0.07 vs. -0.13); ﬂu-like syndrome (-0.09 vs.
-0.13); stomatitis (-0.10 vs. -0.15); 1-day out/inpatient care for
grade 3/4 toxicity (-0.11 vs. -0.15); symptomatic melanoma
(-0.11 vs. -0.22); and hospitalization for grade 3/4 toxicity
(-0.13 vs. -0.22). CONCLUSION: The development process for
these standardized health states for advanced melanoma can
serve as a model for developing disease-speciﬁc health states
that incorporate both intended treatment responses and adverse
events. PR and SD are preferred, and symptomatic melanoma
and hospitalization for toxicity yield the highest disutilities. The
method of decrementing utility values by subtracting toxicity
utility weights holds promise for assigning utilities to serious
diseases treated with toxic therapies.
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OBJECTIVE: There is limited experience with patient-reported
health status and health-related quality of life (HRQL) in survi-
vors of cancer in childhood in low-income countries. The purpose
of this study was to collect these measurements in Brazil, test
hypotheses about differences among diagnostic groups, and
compare the results with those from other countries in an overall
assessment of the construct validity of the HUI3. METHODS:
Survivors were eligible if: diagnosed with cancer in childhood;
attending the long-term follow-up clinic for one treatment center;
at least 8 years off therapy; cancer free, literate; and at least
13 years of age. Health status measurements were collected in
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